← FDA DRUG APPROVALS

FDA ANDA · ANDA215381

MICAFUNGIN

micafungin sodium

Sponsor: MEITHEAL

APPLICATION
ANDA215381
TYPE
ANDA
ORIGINAL APPROVAL
2022-09-28
LATEST ACTION
2022-09-28
ROUTE
INTRAVENOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

MICAFUNGIN SODIUMPrescription
MICAFUNGIN SODIUM EQ 50MG BASE/VIAL · INJECTABLE · INTRAVENOUS
MICAFUNGIN SODIUMPrescription
MICAFUNGIN SODIUM EQ 100MG BASE/VIAL · INJECTABLE · INTRAVENOUS

Approval history

2022-09-28UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →